Lupus erythematosus-like disease due to hydrazine
Authors:
- Marcus M. ReidenbergMRMarcus M. Reidenberg
- Pamela J. DurantPDPamela J. Durant
- Robert A. HarrisRHRobert A. Harris
- Grace De BoccardoGBGrace De Boccardo
- Robert LahitaRLRobert Lahita
- Kurt H. StenzelKSKurt H. Stenzel
- 1 August 1983
- journal article
- case report
- Published by Elsevier in The American Journal of Medicine
- Vol. 75 (2) , 365-370
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: Comparison with procainamideThe American Journal of Cardiology, 1980
- HYDRALAZINE-INDUCED SYSTEMIC LUPUS ERYTHEMATOSUS: INFLUENCE OF HLA-DR AND SEX ON SUSCEPTIBILITYThe Lancet, 1980
- Acetylator phenotype in idiopathic systemic lupus erythematosusArthritis & Rheumatism, 1980
- Antibodies to Nuclear Antigens in Patients Treated with Procainamide or AcetylprocainamideNew England Journal of Medicine, 1979
- Remission of Procainamide-Induced Lupus Erythematosus with N-Acetylprocainamide TherapyAnnals of Internal Medicine, 1979
- Effect of Acetylator Phenotype on the Rate at Which Procainamide Induces Antinuclear Antibodies and the Lupus SyndromeNew England Journal of Medicine, 1978
- Clinical consequences of polymorphic acetylation of basic drugsClinical Pharmacology & Therapeutics, 1977
- Disease and Acetylation PolymorphismClinical Pharmacokinetics, 1977
- Acetylator Phenotype in Patients with Hydralazine‐induced Lupoid SyndromeActa Medica Scandinavica, 1976
- Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritisThe American Journal of Medicine, 1973